NASDAQ:CCXIChemoCentryx Stock Price, Forecast & News

ChemoCentryx's stock was trading at $41.54 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CCXI stock has increased by 39.6% and is now trading at $58.01. View which stocks have been most impacted by Coronavirus.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last year. There are currently 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ChemoCentryx.

ChemoCentryx is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for ChemoCentryx.

ChemoCentryx Inc (NASDAQ:CCXI) released its quarterly earnings results on Monday, May, 11th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by $0.05. The biopharmaceutical company earned $6.01 million during the quarter, compared to analysts' expectations of $8.90 million. ChemoCentryx had a negative net margin of 192.93% and a negative return on equity of 100.55%. View ChemoCentryx's earnings history.

9 Wall Street analysts have issued twelve-month target prices for ChemoCentryx's stock. Their forecasts range from $54.00 to $102.00. On average, they expect ChemoCentryx's stock price to reach $70.11 in the next year. This suggests a possible upside of 20.9% from the stock's current price. View analysts' price targets for ChemoCentryx.

Media stories about CCXI stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. ChemoCentryx earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View the latest news about ChemoCentryx.

ChemoCentryx saw a increase in short interest in June. As of June 15th, there was short interest totaling 3,790,000 shares, an increase of 34.4% from the May 31st total of 2,820,000 shares. Based on an average daily trading volume, of 661,800 shares, the short-interest ratio is currently 5.7 days. Approximately 8.6% of the shares of the company are short sold. View ChemoCentryx's Current Options Chain.

Some companies that are related to ChemoCentryx include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Ionis Pharmaceuticals (IONS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ChemoCentryx investors own include Exelixis (EXEL), Energy Transfer LP Unit (ET), Dynavax Technologies (DVAX), Amicus Therapeutics (FOLD), Gilead Sciences (GILD), Arrowhead Pharmaceuticals (ARWR), Advanced Micro Devices (AMD), Opko Health (OPK), NVIDIA (NVDA) and Inovio Pharmaceuticals (INO).

ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."

Shares of CCXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CCXI stock can currently be purchased for approximately $58.01.

ChemoCentryx has a market capitalization of $3.59 billion and generates $36.13 million in revenue each year. The biopharmaceutical company earns $-55,490,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. ChemoCentryx employs 82 workers across the globe.

The official website for ChemoCentryx is www.chemocentryx.com.

ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company can be reached via phone at 650-210-2900 or via email at [email protected]